Bioavailability of Terpenes and Postprandial Effect on Human Antioxidant Potential. An Open‐Label Study in Healthy Subjects

Abstract

Results demonstrate the terpene bioavailability pattern after oral administration of Mastiha. Terpenes are potential mediators of antioxidant defense in vivo.

Regulation of faecal biomarkers in inflammatory bowel disease patients treated with oral mastiha (Pistacia lentiscus) supplement: A double‐blind and placebo‐controlled randomised trial

“…The above findings could also point towards anti‐inflammatory properties of the mastiha terpenes, which have been shown to be absorbed and bioavailable in the systemic circulation in healthy humans (Papada et al, ).…”

“…The mastiha group received natural mastiha supplement at a dose of 2.8 g daily (four tablets × 700‐mg mastiha), whereas the placebo group received identical placebo tablets. This dose was chosen based on a recently published bioavailability study on healthy men, where an acute dose of 10 g of mastiha was well tolerated and no side effects were observed (Papada et al, ). Preclinical data in 2,4,6‐trinitrobenzene sulfonic acid colitic mice showed effectiveness in a daily dose of 100‐mg/kg body weight (Gioxari et al, ).…”

“…Chia) according to European Pharmacopoeia monograph (01/2008:1876). It is rich in terpenic acids with its main triterpenic acids, mastihadienonic, and isomastihadienonic, being absorbed and bioavailable in humans (Assimopoulou & Papageorgiou, ; Papada et al, ; Paraschos et al, ). Additionally, it contains arabinogalactan‐proteins (AGPs; Kottakis, Kouzi‐Koliakou, Pendas, Kountouras, & Choli‐Papadopoulou, ), and some simple phenols have also been detected, however, in low concentrations or even in traces (Kaliora, Mylona, Chiou, Petsios, & Andrikopoulos, ).…”

Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial

“…The Mastiha group received natural Mastiha at a dose of 2.8g daily (4 tabs x 700 mg Mastiha), while the placebo group received identical placebo Tablets for 6 months, as an adjunct to conventional medical treatment. The choice of this dose was based on a previous pilot study in CD patients experiencing no side effects and a bioavailability study in healthy humans (Kaliora et al 2007a, 2007b, Papada et al 2018. Additionally, standard nutritional advice was provided and patients were encouraged to report adverse effects.…”

“…However, in this resin only simple phenols have been detected, however in low concentrations or even in traces (Kaliora et al, 2004). We have recently reported the absorption and bioavailability of the main triterpenic acids mastihadienonic and isomastihadienonic acids that have been identified in the highly active acidic fraction (Assimopoulou and Papageorgiou 2005;Papada et al, 2018;Paraschos et al, 2007;Xynos et al, 2018). Concentrations of these triterpenic compounds have been determined by Paraschos A C C E P T E D M A N U S C R I P T 5 and coworkers (2007); namely mastihadienonic acid 20.9mg/g mastiha and isomastihadienonic acid 19mg/g mastiha.…”